19 results about "Peramivir" patented technology

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

The present invention relates to a method for preparing a high-purity peramivir intermediate. The method comprises the following steps: Step 1: adding compound II to a reaction kettle, and dropwise adding a sodium borohydride methanol solution; after the dropwise addition is completed, the reaction is stirred at a controlled temperature; purified water and a sodium nitrite solution are added, and the reaction is stirred to prepare compound (III); Step 2: adding acetic anhydride dropwise to compound (III), and the reaction is stirred at a controlled temperature; Step 3: adding a sodium carbonate aqueous solution, stirring, separating the liquids, collecting the organic phase, concentrating under reduced pressure, adding a solvent, stirring and crystallizing, and centrifuging until no obvious liquid flows out; vacuum drying the filter cake to obtain an off-white crude peramivir acetylate (IV); Step 4: refining to obtain an off-white solid peramivir acetylate (IV). #imgabs0#

The present disclosure relates to compositions and methods for treating viral infections. Compositions and methods for treating viral infections include conjugates comprising a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc monomer, an Fc domain, and an Fc binding peptide, albumin, or an albumin binding peptide. In particular, the conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

The invention relates to an amino-acid ester prodrug of peramivir, which has the following structural formula: in the formula, R is L-valine, D-valine and L-isoleucine taking 2, 3-butanediol as a connecting arm, and L-isoleucine, L-alanine, L-valine or D-valine taking 2-methyl-1, 3-propylene glycol as a connecting arm. Mouse in-vivo pharmacokinetic verification shows that the amino-acid ester prodrug of the peramivir has remarkably higher absolute bioavailability and is suitable for being prepared into an oral administration preparation.

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

The invention discloses an application of a Wevir drug in preparation of a drug for resisting canine distemper virus. It is found that 20-100 [mu] M of pirentamivir and ombitasvir have no obvious toxic effect on MDCK cells, and 20 [mu] M of pirentamivir and ombitasvir can significantly inhibit canine distemper virus proliferation, which indicates that pirentamivir and ombitasvir can become a new choice for preparation of anti-canine distemper virus drugs. The pirentamivir and ombitasvir pharmaceutical composition is a new use of an old medicine, the pharmacokinetic data of pirentamivir and ombitasvir which are sold on the market are detailed, the safety is reliable, the development of the new use can be quickly performed for second-stage clinical evaluation, the research and development period is shortened, the development cost is saved, and resources can be utilized to the maximum extent.

The present disclosure provides a pharmaceutical preparation, which comprises the following preparation raw materials: an active ingredient selected from one of peramivir, zanamivir, lanimivir and a hydrate or solvate thereof; the carboxylic acid anion donor is selected from at least one of pamoic acid and hydroxynaphthoic acid; and a first pH adjusting agent, which is an alkaline pH adjusting agent.

Compositions and methods for treating viral infections include conjugates comprising a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc monomer, an Fc domain, an Fc binding peptide, an albumin protein, or an albumin binding peptide. In particular, the conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

The invention relates to a conjugate for inhibiting virus replication and a preparation method and application thereof. The present invention relates to a conjugate comprising a dimer or trimer of a moiety that inhibits influenza virus neuraminidase (e.g., zanamivir, peramivir, oseltamivir, or an analog thereof) coupled to an Fc domain monomer, an Fc domain, an Fc binding peptide, an albumin, or an albumin binding peptide. The conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

Compositions and methods for treating viral infections include conjugates containing a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, Fc domain, and Fc binding peptide, albumin, or albumin binding peptide. In particular, the conjugates can be used to treat viral infections (e.g., influenza virus infections).

The invention relates to a peramivir injection and a preparation method thereof. The invention relates to a peramivir injection and a preparation method thereof, the peramivir injection is characterized in that every 3000 ml of the peramivir injection contains 30 g of peramivir, thiourea and cyclanic acid sodium, preferably, 3.2 g of thiourea and 2.5 g of cyclanic acid sodium are contained in every 3000 ml of the peramivir injection, and the preferable specification is 15 ml: 0.15 g. The peramivir injection prepared according to a prescription process has extremely high quality stability and is obviously superior to the prior art.

The invention provides a production process of a peramivir injection, which comprises the following steps: A) mixing peramivir, sodium chloride and water for injection, stirring and dissolving to obtain a mixed liquid medicine; the mixing temperature is below 20 DEG C; and B) sterilizing the liquid medicine, filtering, filling and sterilizing to obtain the peramivir injection. The peramivir injection is high in stability, high in yield and low in impurity content by adopting production processes such as low-temperature matched filtration. Meanwhile, the production process is simple, and a buffering agent, a pH regulator and the like do not need to be added.

This invention relates to the field of pharmaceutical analysis technology, and provides a method for detecting enantiomers in peramivir sodium chloride injection. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a column packed with α1-acidic glycoprotein-bonded silica gel; a mobile phase consisting of a mixture of 0.02 mol / L ammonium dihydrogen phosphate solution and 0.02 mol / L diammonium hydrogen phosphate solution at a volume ratio of 45:55 to 55:45; a detection wavelength of 205 nm; a flow rate of 0.25 to 0.35 mL / min; and a column temperature of 18 to 22 °C. Before detection, a test solution, a reference solution, and a system suitability solution are prepared, and each solution is accurately injected into the HPLC system. The chromatograms are recorded, and the enantiomer content is calculated. The advantages of this invention are: simple operation, no sodium chloride interference, and accurate quantitative detection of enantiomers in peramivir sodium chloride injection.

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

The invention belongs to the technical field of medicine detection, and particularly relates to a method for detecting and analyzing related substances of peramivir injection, which adopts an HPLC (High Performance Liquid Chromatography) analysis method, and adopts octadecylsilane chemically bonded silica as a filler as a chromatographic column; the mobile phase A is a phosphate buffer solution, and the mobile phase B is acetonitrile; carrying out gradient elution on the mobile phase; the detection wavelength is 205 to 215 nm; according to the method, impurities A, C, D and H can be effectively separated from peramivir, the content of the impurities is objectively and quantitatively analyzed, and product quality control is facilitated.

The present disclosure provides a pharmaceutical formulation, wherein raw materials for formulating the pharmaceutical formulation comprise: an active ingredient which is one selected from the group consisting of peramivir, zanamivir, laninamivir, and hydrates or solvates thereof; a carboxylic acid anion donor which is at least one selected from the group consisting of pamoic acid and hydroxynaphthoic acid; and a first pH regulator which is an alkaline pH regulator.

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

The invention relates to the field of food detection, in particular to an analysis and detection method for antiviral drug residues in eggs, which comprises the following steps: S1, sample pretreatment: 1.1, sample preparation: shelling eggs, homogenizing, and storing at 4 DEG C; 1.2, extracting: weighing a homogenate sample, extracting twice by using 90% acetonitrile-1% formic acid solution, and merging supernate; 1.3, purifying and redissolving: purifying the supernate through an EMR-Lipid solid-phase extraction column, collecting eluent, blowing the eluent to be nearly dry at 40 DEG C by nitrogen, redissolving by using a formic acid-methanol solution, and filtering to obtain a matrix extracting solution; s2, preparing a standard solution; s3, instrument detection: performing chromatography-tandem mass spectrometry detection; s4, quantitative analysis: calculating the residual quantity of the eight antiviral drugs in the eggs according to the quantitative ion peak area by adopting a matrix matching standard curve external standard method. The precise detection of eight viruses, namely nevirapine, peramivir, famciclovir, rimantadine, amantadine, oseltamivir, imiquimod and memantine, is realized.

The invention provides purification and impurity separation equipment and process for a peramivir intermediate, and relates to the technical field of purification and impurity removal of peramivir intermediates. The purification and impurity separation equipment for the peramivir intermediate comprises a rack, an upper separation chamber is arranged on the upper portion in the rack, a lower separation chamber is arranged on the lower portion in the rack, an upper separation mechanism used for secondary purification and impurity separation of the peramivir intermediate is arranged in the upper separation chamber, and a lower separation mechanism used for secondary purification and impurity separation of the peramivir intermediate is arranged in the lower separation chamber. A lower separation mechanism used for primary purification and impurity separation of the peramivir intermediate is arranged in the lower separation chamber, and a transfer mechanism used for conveying the peramivir intermediate to the upper separation mechanism by the lower separation mechanism is arranged on one side of the rack. By means of secondary purification, the purity of the peramivir intermediate is higher, it is guaranteed that the peramivir intermediate cannot be subjected to secondary pollution through the fact that the driving mechanism and the screening mechanism are separated, and the screening efficiency is high.